Login
Companies $CLYM
$9.82 -$0.12 (1.23%) After hours
Climb Bio, Inc. logo

Climb Bio, Inc.

climbbio.com

What Do They Do?

Develops antibody drug candidates for people with immune-mediated diseases, including kidney and systemic autoimmune disorders.

How Do They Make Money?

No revenue reported yet.

How Are They Changing?

Therapeutic focus The focus moved from chemical drug candidates for neuronal excitability disorders, such as epilepsy and pain, to antibody candidates for immune-mediated diseases, including kidney and systemic autoimmune disorders.

Who Do They Compete With?

Competes with Amgen, IASO Biotherapeutics, AbbVie, Cullinan Therapeutics, Zenas BioPharma, L. Hoffmann-La Roche, Merck &, Novartis, Bristol Myers Squibb, Cabaletta Bio, Kyverna Therapeutics, Nkarta, Otsuka Pharmaceutical, Jade Biosciences, Vertex Pharmaceuticals, Vera Therapeutics, Biogen, Takeda Pharmaceutical, Biohaven, and argenx

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support